DEVELOPMENT
Grovrito is developing treatments for acantholytic diseases for which there are no approved tratments.
Our lead drug has shown early efficacy for treatment and elimination of the symptoms of Grover’s Disease including elimination of papules and papulovesicles, redness and pruritus.
Primary Acantholytic diseases include:
Grover’s Disease (GD),
Hailey-Hailey disease (HHD),
Darier’s disease,
Staphylococcal scaled skin syndrome (SSSS),
Bullous impetigo,
Pemphigus vulgaris,
Pemphigus follaceus and their variants.
In these primary acantholytic diseases, dissociation and disintegration of desmosomes leads to the separation of keratinocytes.